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Abstract
Complications in pregnancy elevate fetal norepinephrine (NE) concentrations. Previous studies in 
NE-infused sheep fetuses revealed that sustained exposure to high NE resulted in lower expression 
of α2-adrenergic receptors in islets and increased insulin secretion responsiveness after acutely 
terminating the NE infusion. In this study, we determined if the compensatory increase in insulin 
secretion following chronic elevation of NE is independent of hyperglycemia in sheep fetuses and 
whether it is persistent in conjunction with islet desensitization to NE. Following an initial 
assessment of glucose-stimulated insulin secretion (GSIS) at 129±1 days of gestation, fetuses were 
continuously infused for seven days with NE and maintained at euglycemia with a maternal 
insulin infusion. Fetal GSIS studies were again performed on days 8 and 12. Adrenergic sensitivity 
was determined in pancreatic islets collected at day 12. NE infusion increased (P<0.01) fetal 
plasma NE concentrations and lowered (P<0.01) basal insulin concentrations compared to vehicle-
infused controls. GSIS was 1.8-fold greater (P<0.05) in NE-infused fetuses compared to controls 
at both one and five days after discontinuing the infusion. Glucose-potentiated arginine-induced 
insulin secretion was also enhanced (P<0.01) in NE-infused fetuses. Maximum GSIS in islets 
isolated from NE-infused fetuses was 1.6-fold greater (P<0.05) than controls, but islet insulin 
content and intracellular calcium signaling were not different between treatments. The half-
maximal inhibitory concentration for NE was 2.6-fold greater (P<0.05) in NE-infused islets 
compared to controls. These findings show that chronic NE exposure and not hyperglycemia 
produce persistent adaptations in pancreatic islets that augment β-cell responsiveness in part 
through decreased adrenergic sensitivity.
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Introduction
Fetal stress imposed by complications such as ischemic placental disease leads to prolonged 
increases in fetal circulating catecholamines (Okamura et al. 1990; Greenough et al. 1990; 
Ananth & Vintzileos 2006; Ananth & Friedman 2014). Elevated epinephrine and 
norepinephrine (NE) concentrations in the fetus are primary determinants for adaptive 
changes in metabolism and reduced growth rates (Apatu & Barnes 1991; Milley 1997; 
Bassett & Hanson 1998; Davis et al. 2015). Catecholamines suppress insulin release via α2-
adrenergic receptors (α2-ARs) on pancreatic β-cells (Sperling et al. 1984; Jackson et al. 
2000; Yates et al. 2012a). In an ovine model of placental insufficiency-induced intrauterine 
growth restriction (PI-IUGR), glucose-stimulated insulin secretion (GSIS) was attenuated, in 
part, by elevated catecholamine concentrations (Limesand et al. 2006; Macko et al. 2016). 
Pharmacological adrenergic blockade in IUGR sheep fetuses ameliorated the deficiency in 
GSIS, even though β-cell mass was substantially lower (Leos et al. 2010; Macko et al. 2013; 
Limesand et al. 2013). To define the islet response to chronic adrenergic stimulation during 
gestation, we infused NE into normal sheep fetuses for seven days and showed that 
continuous exposure to high NE concentrations suppressed fetal insulin secretion and raised 
fetal glucose concentrations. Moreover, three hours after terminating the chronic NE 
infusion, we observed an enhancement in insulin secretion responsiveness to glucose and 
arginine challenges (Chen et al. 2014). Expression levels of α2-AR and Gαi-2 protein were 
also reduced in islets from this cohort of NE fetuses (Chen et al. 2014). Our findings from 
these two distinct models of chronic hypercatecholaminemia, PI-IUGR and NE infusion, 
indicate that sustained adrenergic stimulation produces a compensatory augmentation in β-
cell responsiveness. Therefore, we propose that NE-induced adaptations in fetal islets may 
produce a discord between insulin secretion and insulin action during the transition from 
fetal to postnatal life, and predispose offspring to metabolic complications.
In this study we test the hypothesis that the compensatory increase in insulin secretion 
responsiveness and adrenergic receptor desensitization in islets persist in sheep fetuses after 
a period of chronic hypercatecholaminemia and are not dependent upon fetal hyperglycemia. 
In our previous work, glucose concentrations were incongruent between IUGR and NE-
infused fetuses and both hypo- and hyperglycemia negatively affect β-cell responsiveness 
(Carver et al. 1995; Green et al. 2012; Chen et al. 2014; Macko et al. 2016). To avoid 
confounding results from glucose, we maintained euglycemic conditions in the fetus during 
the NE infusion with a simultaneous maternal infusion of insulin. We show that the 
compensatory increase in insulin secretion responsiveness to glucose and arginine 
stimulation was present five days after discontinuing the NE treatment. Furthermore, 
isolated islets from the NE fetuses exhibited greater GSIS and NE desensitization.
Materials and Methods
Animal preparation
Studies were conducted in 15 pregnant Columbia-Rambouillet crossbred ewes carrying a 
singleton fetus (Nebeker Ranch, Lancaster, CA). Ewes were fed Standard-Bread Alfalfa 
Pellets (Sacate Pellet Mills, AZ) and provided water and salt ad libitum. Indwelling vascular 
catheters were surgically placed into ewes and fetuses for arterial blood sampling and 
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intravenous infusions at 123 ± 1 days gestational age (dGA). Animal husbandry was 
performed as previously reported (Chen et al. 2014; Macko et al. 2016). All animal 
procedures were approved by the Institutional Animal Care and Use Committee and 
performed at the University of Arizona, which is accredited by the American Association for 
Accreditation of Laboratory Animal Care.
Experimental treatments
Sheep fetuses were randomly assigned to control (n = 7) or NE (n = 8) groups at 129 ± 1 
dGA. Control fetuses received an infusion of diluent (0.3% ascorbic acid in 0.9% saline), 
and ewes received an infusion of diluent (0.9% saline with 0.5% BSA). NE fetuses received 
an infusion of NE (Norepinephrine Bitartrate, Bedford Laboratories, OH; 1–4 μg/min; IV) 
for 7 days at preset rates for each day of treatment (day 1 at 1 μg/min, days 2–4 at 2 μg/min, 
and days 5–7 at 4μg/min; (Chen et al. 2014)). Insulin (Humulin R; Eli Lilly, Indianapolis, 
IN; 30–60 pmol/min/kg) was intravenously infused into ewes to maintain euglycemic 
conditions in fetuses during NE infusion (Limesand & Hay, Jr. 2003; Rozance et al. 2006). 
The rates of NE infusion were previously shown to recapitulate physiological concentrations 
observed in response to fetal hypoxemia in human and sheep (Greenough et al. 1990; Yates 
et al. 2012a; Chen et al. 2014). All infusions were terminated on day 7 of treatment, 24 
hours prior to the second GSIS study.
Experimental design and insulin secretion studies
Three GSIS studies were performed before (GSIS-pre), 1 day after (GSIS-1d), and 5 days 
after (GSIS-5d) the chronic infusion in all but one control fetus, where the final GSIS study 
was lost due to loss of catheter patency. The GSIS studies were conducted as described 
previously (Limesand et al. 2006; Leos et al. 2010). Briefly, a continuous transfusion of 
maternal arterial blood into the fetus (10 mL/h) was started 30 min prior to sampling and 
maintained for the duration of the study to compensate for blood collection. Three baseline 
blood samples were collected within the 20 minutes preceding the dextrose bolus at 5–7 
minute intervals. The square-wave hyperglycemic clamp was initiated with a dextrose bolus 
of 1.19 ± 0.04 mmol/kg estimated fetal weight followed by a constant infusion of 33% 
dextrose to increase and maintain fetal arterial plasma glucose concentration at 2.5 
± 0.1mmol/L, which produces a near-maximal GSIS response (Green et al. 2011). During 
the hyperglycemic clamp, three fetal arterial plasma samples were collected at 45, 50, and 
55 min during steady state conditions when concentrations varied less than ± 6% of the 
mean and showed no systematic trend with time. Averages for baseline and hyperglycemia 
steady state periods were calculated for comparisons. Maximal insulin secretion 
responsiveness was measured with a follow-on arginine bolus (0.5 mmol/kg estimated fetal 
weight) as described previously (Gresores et al. 1997; Green et al. 2012).
Biochemical analysis
Fetal arterial blood samples were collected and prepared for analysis as described previously 
(Chen et al. 2014). Fetal blood samples were collected for blood gasses, pH, and oximetry 
measurements with an ABL 725, (temperature-corrected to 39.1°C; Radiometer, 
Copenhagen, Denmark). Plasma glucose and lactate concentrations were measured 
immediately with a YSI model 2700 SELECT Biochemistry Analyzer (Yellow Springs 
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Instruments, Yellow Springs, OH). Plasma samples for insulin and NE measurements were 
stored at −80°C. Insulin concentrations were measured with an ovine insulin ELISA 
(ALPCO Diagnostics, Windham, NH) that had a 9.1% inter-assay and 8.5% intra-assay 
coefficients of variation. NE concentrations were measured by Noradrenaline ELISA (Labor 
Diagnostika Nord GmbH & Co.KG, Nordhorn, Germany) that had a 22.5% inter-assay and 
19.6% intra-assay coefficients of variation.
Necropsy and islet isolation
After GSIS-5d, animals were recovered for 3–5 hours before ewes and fetuses were 
euthanized with an overdose of sodium pentobarbital (86 mg/kg) and phenytoin sodium (11 
mg/kg, Euthasol; Virbac Animal Health, Fort Worth, TX). Fetuses and fetal organs were 
dissected and weighed. The hepatic portion of pancreas was collected for islet isolation 
(Limesand et al. 2006). The splenic portion of pancreas was fixed in 4% paraformaldehyde 
overnight and prepared for histological analysis as described previously (Cole et al. 2009).
Islets were isolated after the fetal pancreas was digested in Krebs-Ringer Buffer (KRB) with 
Collagenase V (0.425 mg/mL; Sigma) and DNase I (2 μU/mL; Roche Diagnostics, 
Mannheim, Germany) as described previously (Limesand et al. 2006; Chen et al. 2014; 
Rozance et al. 2015). Isolated islets were washed in KRB containing 0.5% BSA (KRB-
BSA). Islets were cultured overnight in RPMI-1640 medium (Sigma-Aldrich) supplemented 
with 2% fetal bovine serum, 2.8 mmol/L glucose, and penicillin–streptomycin (50 U and 50 
mg; Sigma-Aldrich) at 37°C with 95% O2-5% CO2 (Limesand et al. 2006; Green et al. 
2012).
Islet static incubations
Fetal islets from control (n = 6) and NE fetuses (n = 6) were washed twice in KRB-BSA and 
a third time in KRB-BSA supplemented with 10 μmol/L forskolin (Sigma-Aldrich). All 
media was equilibrated to 37°C and gassed with 95% O2-5% CO2. Ten islets were 
handpicked (3–4 replicates/condition for each fetus) and incubated at 37°C in 1 mL KRB-
BSA-forskolin media with high (11.1 mmol/L) and no (0 mmol/L) glucose, high glucose 
plus NE (0.1 nmol/L – 10 μmol/L), and 1.1 mmo/L glucose plus 30 mmol/L KCl. After a 1-
hour static incubation, islets were pelleted by centrifugation (800 x g) at 4°C for 3 min. The 
media was removed and insulin was extracted from islets with acid-ethanol (1 M HCl in 
70% ethanol) to determine the islet insulin content. The effectiveness of NE in inhibiting 
insulin secretion was determined by the half-maximal inhibitory concentration (IC50) using 
the dose response equation (log (inhibitor) vs. normalized response; Prism 6, GraphPad 
Software, La Jolla, CA).
Whole-islet calcium dynamics
Islets were incubated overnight on glass coverslips pre-coated with human fibronectin (10 
mg/L in PBS; BD Biosciences, Bedford, MA, USA; (Green et al. 2011)). Islets from control 
and NE fetuses (n = 3/treatment) were washed at 4°C for 10 min with glucose-free Hank’s 
Balanced Salt Solution (HBSS; 5 mmol/L KCl, 0.3mmol/L KH2PO4, 138 mmol/L NaCl, 
0.2mmol/L NaHCO3, 0.3mmol/L Na2HPO4, 20 mmol/L HEPES, 1.3 mmol/L CaCl2 and 
0.4mmol/L MgSO4, pH 7.4) and then loaded with fura-2 acetoxymethylester (2.5 μmol/L; 
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Molecular Probes) in glucose-free HBSS with 0.0025% pluronic acid for 20 min at 4°C and 
20 min at 25°C. The islets were rinsed, incubated in HBSS with 1.1 mmol/L glucose for 10 
min at 37°C, and mounted onto the stage of an Olympus IX-70 microscope. Fura-2 was 
alternately excited at 340 and 380 nm and emitted light (508 nm) captured on a Photometrics 
CH-250 camera as described previously (Lynch et al. 2008). Images were acquired at 0.5–1 
minute intervals in the following series of media conditions: low glucose (1.1 mmol/L) for 5 
min; high glucose (11.1 mmol/L) for 20 min; 30 mmol/L KCl for 5 min; and 10 μmol/L 
ionomycin for 4 min. Data were analyzed for 25–67 fields of view obtained from 2–6 islets 
per fetus (coefficient of variation between islets = 6.1%).
Histology of fetal pancreatic endocrine cells
Pancreatic tissue sections (6 μm) were cut from frozen OCT-embedded control (n = 7) and 
NE (n = 6) fetuses and prepared for histological evaluation as described previously (Cole et 
al. 2009; Leos et al. 2010). Endocrine cells were identified with guinea pig anti-porcine 
insulin (1:500; Dako, Carpinteria, CA), mouse anti-porcine glucagon (1:500; Sigma-
Aldrich), rabbit anti-human somatostatin (1:500; Dako), and rabbit anti-human pancreatic 
polypeptide (1:500; Dako). Immunocomplexes were detected with affinity-purified 
secondary antiserum conjugated to Cy2 (rabbit), Texas Red (mouse), or 7-amino-4-
methylcoumarin-3-acetic acid (AMCA, guinea pig; Jackson ImmunoResearch Laboratories, 
West Grove, PA) diluted 1:500 in PBS with 1% BSA. Fluorescent staining was visualized on 
a Leica DM5500 microscope system and digitally captured with a Spot Pursuit 4 Megapixel 
CCD camera (Diagnostic Instruments, Sterling Heights, MI). Morphometric analysis was 
performed with ImagePro 6.0 software (Media Cybernetics, Silver Spring, MD). Positive 
areas were determined from 25 fields of view (FOV = 0.39 mm2) on two pancreas sections 
per animal separated by ≥ 120μm intervals (total area = 19.5 mm2; coefficient of variation 
between sections = 10.7%).
Statistical analysis
Differences between treatments (control and NE) for animal weights, daily intake, islet IC50, 
and pancreas morphology were analyzed by one-way ANOVA (treatments) using the general 
linear means procedure (SAS 9.4, SAS Institute Inc., Cary, NC) and differences were 
determined with Student’s t test. Repeated measurement for biochemical, hematological, and 
hormone from daily samples, GSIS studies, GPAIS studies, and ex vivo islet experiments 
were analyzed by ANOVA using Proc MIXED with fetus as the random effect (SAS 9.4). 
Main effects within GSIS studies were treatment, period, and their interaction. Main effects 
for GPAIS within treatment were study, sample time, and their interaction. When the overall 
ANOVA was significant (α = 0.05), individual means were separated with a least significant 
difference test. Data are presented as the mean ± standard error mean.
Results
Animal weights and daily intake
Maternal body weights were not different between control (56.8 ± 3.9 kg) and NE ewes 
(52.8 ± 3.3 kg). During the treatment, average daily feed and water intake were similar in 
control (1.8 ± 0.1 kg and 7.5 ± 0.9 L) and NE ewes (1.9 ± 0.1 kg and 7.2 ± 0.6 L). Fetal age 
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at necropsy was similar in control (140 ± 1 dGA, 3 male and 4 female) and NE fetuses (141 
± 1 dGA, 7 male and 1 female). Fetal weight was not different between control (3.96 ± 0.23 
kg) and NE fetuses (4.02 ± 0.20 kg).
Daily fetal blood parameters
Prior to chronic infusions, fetal plasma glucose, insulin, NE, and blood PaO2 were not 
different between experimental groups (Figure 1). During the 7-day infusion, average NE 
concentrations were higher (9.26 ± 0.87 ng/mL vs. 0.88 ± 0.11ng/mL, P < 0.01), insulin 
concentrations were lower in NE-fetuses compared to controls (0.12 ± 0.01 μg/L vs. 0.43 
± 0.02 μg/L, P < 0.01), and glucose concentrations were not different. NE fetuses also had 
higher blood PaO2 than controls (27.3 ± 0.5 mmHg vs. 20.8 ± 0.3 mmHg, P < 0.01). There 
was no treatment by day interaction for NE, glucose, insulin, or PaO2 during this period.
During the 5 days post-infusion, average plasma NE concentrations (2.46 ± 0.41 ng/mL vs. 
0.61 ± 0.07 ng/mL; P < 0.01) and blood PaO2 (23.0 ± 0.4 mmHg vs. 20.1 ± 0.4 mmHg, P < 
0.01) remained elevated in NE fetuses compared to controls, respectively, but both 
measurements were lower (P < 0.05) after infusion than during infusion (Figure 1). Glucose 
and insulin concentrations were not different between treatments after the chronic infusion 
ended. There was no treatment by day interaction for any of these variables.
Fetal glucose-stimulated insulin secretion
By design, glucose concentrations were increased to 2.5 ± 0.1 mmol/L (P < 0.01) from 
baseline during the hyperglycemic period of all three GSIS studies (Figure 2). Baseline and 
hyperglycemic glucose concentrations were not different between treatments in any GSIS 
studies. The glucose infusion rate to maintain the hyperglycemic clamp also was not 
different between treatment groups (Table 1).
In the GSIS-pre study, baseline insulin concentrations at either period were not different 
between treatments and increased (P < 0.001) with hyperglycemia similarly in both 
treatment groups (Figure 2). Baseline insulin concentrations also were not different between 
NE and control fetuses in GSIS-1d or GSIS-5d studies, but insulin concentrations during the 
hyperglycemic periods were greater (P < 0.05) in NE fetuses than controls in both studies. 
Insulin secretion responsiveness (difference between baseline and hyperglycemic insulin 
concentrations) was not different among three GSIS studies in control fetuses. In NE fetuses, 
however, insulin secretion responsiveness was greater (P < 0.01) in GSIS-1d (1.46 ± 0.36 
μg/L) and GSIS-5d (1.77 ± 0.44 μg/L) compared to GSIS-pre (0.66 ± 0.12 μg/L).
Blood gas, pH, hematocrit, plasma lactate, and plasma NE were not different between 
treatments in GSIS-pre, although differences in period means were found; there was no 
treatment by period interaction (Table 1). In GSIS-1d, NE fetuses had greater PaO2 (25.4 
± 0.5 mmHg vs. 20.0 ± 0.3 mmHg, P < 0.01), blood oxygen content (4.0 ± 0.1 mmol/L vs. 
3.1 ± 0.1 mmol/L, P < 0.05) and NE concentrations (3.33 ± 0.42 ng/mL vs. 0.61 ± 0.05 
ng/mL, P < 0.01) than controls, respectively. The blood PaCO2 values were lower in NE 
fetuses than controls (46.7 ± 0.5 mmHg vs. 51.0 ± 0.3 mmHg, P < 0.01), while pH, 
hematocrit, and lactate were not different. In GSIS-5d NE remained greater than controls 
(1.54 ± 0.14 ng/mL vs. 0.62 ± 0.07 ng/mL, P < 0.05; Table 1).
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Fetal glucose-potentiated arginine-induced insulin secretion
GPAIS was enhanced in NE fetuses following infusion but controls were unaffected (Figure 
3). Average GPAIS insulin concentrations in NE fetuses were greater (P < 0.01) in 
GPAIS-1d (4.02 ± 0.39 μg/L) and GPAIS-5d (3.64 ± 0.35 μg/L) compared to GPIAS-pre 
(2.66 ± 0.19 μg/L), which was similar to all three control GPAIS studies.
Islet responsiveness
Insulin secretion rates from isolated fetal sheep islets were measured in the presence of 11.1 
mmol/L glucose and various NE concentrations (Figure 4A). Maximum glucose-stimulated 
insulin secretion was greater in NE islets than control islets (2.20 ± 0.27 ng/islet/h vs. 1.38 
± 0.24 ng/islet/h, P < 0.05). Minimum insulin secretion rates with NE inhibition were not 
different between NE (0.74 ± 0.18 ng/islet/h) and control islets (0.68 ± 0.15 ng/islet/h), and 
these rates were also not different from incubations with no glucose. In islet incubations 
with 30 mmol/L KCl, insulin secretion rates were greater (P < 0.05) than other conditions 
but not different between treatments (NE, 8.84 ± 1.47 ng/islet/h vs. control, 5.66 ± 1.91 ng/
islet/h). The IC50 concentration was greater (P < 0.05) for NE than control islets (Figure 
4B). Insulin contents of isolated islets were not different between NE and control fetuses 
(Figure 4C).
Cytosolic calcium concentrations at 1.1 mmol/L glucose were not different between NE and 
control islets (340/380 ratio of 0.66 ± 0.01 in NE and 0.67 ± 0.06 in controls). High glucose 
concentrations and 30 mmol/L KCl increased intracellular calcium, but means were not 
different between treatments (0.71 ± 0.01 in NE vs. 0.73 ± 0.07 in control for high glucose, 
and 1.24 ± 0.08 in NE vs. 1.46 ± 0.20 in control for KCl).
Pancreatic endocrine cell area
There were no differences in the total area staining positive for insulin (β-cells), glucagon 
(α-cells), or the combination of somatostatin (δ-cells) and pancreatic polypeptide cells (F-
cells) between treatments (Table 2).
Discussion
Fetal stress associated with placental dysfunction chronically elevates catecholamines 
(Okamura et al. 1990; Greenough et al. 1990). In this study, we demonstrate that sustained 
exposure to elevated NE directly produces lasting adaptations in fetal β-cells. The 
compensatory increase in insulin secretion responsiveness to glucose and arginine was still 
observed five days after cessation of the NE infusion. Furthermore, we confirmed enhanced 
insulin secretion to glucose was intrinsic to the islets following isolation. Although the 
increased β-cell responsiveness to glucose and arginine was not explained by differences in 
β-cell mass, insulin content, or intracellular calcium signaling, the β-cells remained 
desensitized to adrenergic stimulation, which supports previous findings that show lower 
expression of adrenergic receptors and signaling molecules (Chen et al. 2014). Previously, 
IUGR fetuses with elevated catecholamines exhibited improved β-cell responsiveness during 
adrenergic blockade, indicating adaptive programming effects from chronic adrenergic 
stimulation are present (Leos et al. 2010; Macko et al. 2013). In these previous studies, we 
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found the compensatory increase in insulin secretion responsiveness immediately after 
reducing the adrenergic stimulation, whereas here we show the enhancement was maintained 
for five days following removal of elevated adrenergic stimulation indicating that the effects 
were programmed.
Enhanced insulin secretion responsiveness to secretagogues and adrenergic desensitization 
represent two functional adaptations in the β-cell that persisted well beyond the end of NE 
infusion. These findings expand our previous work where we observed a compensatory 
increase in insulin secretion three hours after terminating the NE infusion and also showed 
lower expression of α2-ARs and Gαi-2 protein in fetal sheep islets. It is likely that these two 
effects are interrelated because recent genetic studies reveal that overexpression of α2A-AR 
causes impaired docking and exocytosis of insulin granules (Rosengren et al. 2010; 
Rosengren et al. 2012; Straub & Sharp 2012). However, this tonic inhibition of insulin 
release was alleviated with α2-AR antagonists (Rosengren et al. 2010; Yang et al. 2012). 
Conversely, α2A-AR deficient mice not only lack inhibitory actions in pancreatic β-cell but 
also are hyperinsulinemic and hypoglycemic (Fagerholm et al. 2004; Savontaus et al. 2008). 
The α2-ARs desensitization in pancreatic β-cells found in the present study may, in part, 
explain the compensatory increase in β-cell responsiveness following cessation of 
hypercatecholaminemia because of the loss of tonic inhibition by adrenergic receptors.
Alternative mechanisms for enhanced GSIS and GPAIS responsiveness in the NE fetus may 
include increased metabolic coupling to oxidative phosphorylation or regulation of secretory 
granule exocytosis. We have previously shown that uncoupling protein 2 (UCP2) mRNA 
expression is reduced in NE islets following acute recovery overnight culture in vivo (Chen 
et al. 2014). In β-cells, UCP2 is a negative regulator of insulin secretion because it decreases 
the proton-motive force in the inner mitochondria membrane to circumvent ATP synthesis 
(Zhang et al. 2001; Affourtit & Brand 2006; Affourtit & Brand 2008). Conversely, a 
reduction of UCP2 as identified in islets of NE fetuses enhances insulin secretion (Zhang et 
al. 2006; Robson-Doucette et al. 2011). The reduction in UCP2 expression in NE islets may 
be a direct effect of adrenergic stimulation or an indirect effect because adrenergic 
stimulation decrease rates of glucose metabolism (Laychock & Bilgin 1987; Laychock 1989; 
Dalgaard 2012). Transcriptome expression analysis by high-throughput RNA sequencing of 
NE islets revealed significant increases in chloride channel, calcium activated, family 
member 1 (CLCA1) and FXYD domain containing ion transport regulator 2 and significant 
decreases in solute carrier family 9 member A2 (Na+/H+ Exchanger 2) and inositol 1,4,5-
trisphosphate receptor type 2 in NE islets compared to controls after the acute recovery 
(unpublished data). Although additional work is necessary to determine the role of these ion 
channels in the NE islets, there is evidence that chloride flux across the β-cell membrane can 
modulate exocytotic capacity and alter depolarization kinetics (Barg et al. 1999; Barg et al. 
2001; Thevenod 2002).
In our previous study using chronic 7-day NE infusion, we observed hyperglycemia and 
increased arterial blood oxygen tension in NE fetuses during the treatment. In the present 
study, we maintained fetal glucose concentrations at normal values to eliminate the 
confounding influence of chronic hyperglycemia, which was previously demonstrated to 
negatively influence insulin secretion (Carver et al. 1995; Green et al. 2012). Here, we 
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confirm that the NE-induced compensation in fetal sheep islets is independent of the fetal 
glucose concentrations. Moreover, when we compare the NE fetal cohorts and the PI-IUGR 
fetal sheep cohort that is hypoglycemic (Leos et al. 2010; Macko et al. 2013), we can 
exclude an influence of fetal glucose concentrations for the compensatory enhancement in 
β-cell function following chronic NE exposure because it is present in fetuses with hypo-, 
hyper-, and euglycemic conditions. Similarly, oxygen tension is not expected to affect these 
results because they persist in models with different fetal oxygenation. Acutely, in normal 
sheep fetuses, higher blood PaO2 did not augment GSIS (Jackson et al. 2000), and when 
placental insufficiency-induced IUGR fetuses were oxygenated to normal levels from 
hypoxemia, insulin secretion was enhanced independently of norepinephrine concentrations 
(Macko et al. 2016).
Plasma NE concentrations of NE fetuses remained 5.3-fold and 2.5-fold higher than controls 
at one and five days after terminating NE infusion, respectively. Chronic NE exposure or 
physiological hypoxic challenges in fetal sheep and lambs inhibit catecholamine clearance 
rates in the placenta and lung, which partially explain the prolonged elevation (Chappell et 
al. 1991; Bzoskie et al. 1995; Bzoskie et al. 1997). Also, if α2-ARs on the adrenal 
chromaffin cells were desensitized increased rates of NE synthesis would be expected, 
because the adrenal glands possess short feedback inhibition similar to sympathetic neurons 
(Brede et al. 2003; Moura et al. 2006). Despite the elevation of NE, NE fetuses still had 
significantly higher β-cell responsiveness, indicating that the new levels of catecholamines 
are below effective concentrations to inhibit insulin secretion.
Persistence in enhanced insulin secretion responsiveness resulting from chronically elevated 
NE in utero begins to explain the common occurrence for transient hyperinsulinemic 
hypoglycemia seen in infants born small for gestational age or with perinatal stress (Collins 
et al. 1990; Duvanel et al. 1999; Stanley et al. 2015). The baseline insulin and glucose 
concentrations in NE fetuses are equivalent to controls, but glucose concentrations will 
increase after delivery. If the increased β-cell sensitivity continues postnatally, it is 
anticipated that hyperinsulinemia will pursue and lower neonatal glucose concentrations. 
Hyperinsulinemia and hypoglycemia will be exacerbated by adrenergic receptor 
desensitization because counter regulatory mechanisms for glucose homeostasis will be 
reduced (Hawdon et al. 1993; Rozance & Hay, Jr. 2010; Chen et al. 2010). Although 
management of asymptomatic hypoglycemia is controversial, reoccurring episodes are 
associated with poor neurodevelopment and growth deficits (Duvanel et al. 1999; Rozance & 
Hay, Jr. 2016). Therefore, while the symptoms may resolve, there are potential long term 
consequences to transient hyperinsulinemic hypoglycemia in neonate that may result from 
chronically elevated NE.
In conclusion, chronic elevation of NE concentration, not hyperglycemia, produces a 
compensatory enhancement in β-cell responsiveness to insulin secretagogues after 
terminating the NE infusion in fetal sheep. Improved insulin secretion was intrinsic to 
pancreatic islets, which maintained α2-AR desensitization six days after termination of NE 
infusion, which may contribute to the manifestation of persistent adaptation in β-cells. 
Although previous studies in PI-IUGR fetuses and lambs support peripheral adrenergic 
receptor desensitization that impairs the ability of catecholamines to mobilize free fatty 
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acids (Chen et al. 2010; Yates et al. 2012b; Yates et al. 2016), this is the first study to 
describe programming effects from NE in β-cells. Importantly, the β-cell dysfunction 
created by NE-infusion begins to explain the potential variability in small-for-gestational age 
infants because sustained exposure to high catecholamine levels is found in IUGR infants. 
The enhanced β-cell responsiveness induced by chronic high catecholamine concentrations 
in the fetus will create an imbalance in the insulin disposition index that may impair the 
maturation of glucose homeostasis.
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Figure 1. NE Infusion Inhibits Insulin Concentrations
Daily arterial means are presented for control (circles, n = 7) and NE fetuses (squares, n = 
8). Values for plasma norepinephrine (A), plasma glucose (B), plasma insulin (C) and partial 
pressure of blood oxygen (PaO2, D) were determined for each day of treatment (x-axis). 
Difference (P < 0.05) during the infusion and post-infusion periods are identified with an 
asterisk.
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Figure 2. Persistent Enhancement of GSIS in NE fetuses
Plasma glucose and insulin concentrations are presented for the three GSIS studies, which 
are labeled above the graphs: before (GSIS-pre), 1 day after (GSIS-1d) and 5 days after 
(GSIS-5d) the chronic infusion. Baseline and hyperglycemic steady state period means for 
control (n = 6–7) and NE fetuses (n = 8) were analyzed within each GSIS study. Differences 
(P < 0.05) between control and NE fetuses within the period are identified (*).
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Figure 3. Persistent Enhancement of GPAIS in NE Fetuses
Insulin concentrations are presented for the GPAIS studies in control (A, n = 6–7) and NE 
fetuses (B, n = 8). The arginine bolus is administered at time 0. GPAIS studies were 
conducted before (GPAIS-pre), 1 day after (GPAIS-1d) and 5 days after (GPAIS-5d) the 
chronic treatment. There was no study by time interaction. Study differences (*; P < 0.05) 
for the average insulin concentration were observed in the NE fetuses but not controls.
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Figure 4. Enhanced Glucose Stimulated Insulin Secretion in NE Islets
Pancreatic islets were isolated from control and NE fetuses (n = 6 animals/treatment). A) 
Insulin secretion rates were measured in static incubations that contain 11.1 mmol/L glucose 
and various NE concentrations that ranged from 0–10 μmol/L (y-axis). The bar with 
asterisks indicate that the maximum insulin secretion rate was significantly different (P < 
0.01) between control and NE islets. B) The half maximal inhibitory concentration (IC50) 
was calculated for each treatment. Values represent means ± SEM, and the asterisks 
indicates a difference (P < 0.05) between treatment groups. C) Islet insulin contents were not 
different between treatments.
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Table 2
Endocrine pancreas morphometry.
Control (n = 7) NE (n = 6)
β-cell area, % 2.22±0.43 2.04±0.26
α-cell area, % 1.48±0.19 1.67±0.28
δ- and PP-cell area, % 0.97±0.10 0.98±0.17
Total Endocrine Area, % 4.66 ± 0.67 4.69 ± 0.61
PP, pancreatic polypeptide.
Values are means ± SEM.
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